Latest releases

What are you looking for?

	Latest Annual Report
	Latest teleconference presentation
	Financial calender
	Clinical references
	Investor kit
	Financial glossary

Latest releases

Reports

Each year, Lundbeck produces a wide range of financial reports to inform the investment community, plus documents regarding the environmental status of our production sites. You’ll find them all right here.

View all reports

Share information

There are many factors that contribute to the activity of Lundbeck's shares. Here are some documents and background facts that have proven useful to our shareholders and potential investors.

Keep Updated.
Receive releases by email.

30-Jun-2008

Headline results of Flurizan® in clinical phase III trial

Myriad Genetics, Inc. has today announced the outcome of a clinical phase III trial of Flurizan® (tarenflurbil) in 1,684 patients with mild Alzheimer's disease. The clinical phase III data do not correspond to the data observed in clinical phase II in patients with mild Alzheimer's disease. Lundbeck and Myriad will now investigate the data further to understand the outcome of the trial in which the compound did not meet the two primary endpoints.

16-Jun-2008

Azilect® slows the progression of Parkinson's disease in clinical trial

Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed Azilect® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of Azilect®.

View all releases

Financial calendar

13 August 2008

Interim report for the second quarter of 2008

12 November 2008

Interim report for the third quarter of 2008